Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 16, 2021

Primary Completion Date

November 10, 2024

Study Completion Date

November 10, 2024

Conditions

Skin and Connective Tissue DiseasesSkin DiseasesPigmentation DisorderHypopigmentationBiologicVitiligo

Interventions

DRUG

Tildrakizumab

2 100mg subcutaneous injections Q4W

Trial Locations (1)

Premier Specialists Pty Ltd, Sydney

All Listed Sponsors

lead

Premier Specialists, Australia

OTHER

NCT04971200 - Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo | Biotech Hunter | Biotech Hunter